Form 4: Vor Biopharma Executive Eyal Attar Reports Stock Option Repricing and RSU Acquisition

Eyal Attar, Chief Medical Officer of Vor Biopharma, reports transactions involving stock options and restricted stock units (RSUs) on February 3, 2025, including a stock option repricing.

Summary

• On February 3, 2025, Eyal Attar, the Chief Medical Officer of Vor Biopharma, engaged in transactions involving the company's stock.
• These transactions included the withholding of 1,353 shares to cover tax obligations related to the settlement of restricted stock units (RSUs) at a price of $1.34 per share.
• Attar also acquired 52,500 shares underlying RSUs, which vest in equal quarterly installments over four years starting February 1, 2025.
• Additionally, a stock option award repricing was approved by the Issuer's Board of Directors, effective February 3, 2025, under the 2015 Stock Incentive Plan, 2021 Equity Incentive Plan, and 2023 Inducement Plan.
• The exercise price of the stock option award is $1.34 per share, representing the fair market value on the effective date.
• Attar also reports holding employee stock options with varying exercise prices and expiration dates, some of which were repriced to $1.34.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected for an executive, with the repricing potentially viewed as a positive incentive.

Positives

• The stock option repricing to $1.34 may incentivize Attar, aligning his interests with shareholders.
• The vesting schedule of the RSUs (quarterly over four years) encourages long-term commitment from the executive.

Risks

• The 'Retention Period' for the repriced stock options means that if exercised within 12 months, the options revert to their original exercise price, potentially disincentivizing immediate action based on the repricing.

Future Outlook

The vesting schedules of the RSUs and stock options suggest a continued service expectation for the reporting person.

Industry Context

Stock option repricing is a tool companies use to re-incentivize employees when the stock price has fallen below the original option exercise price. This is a common practice in the biotech industry, which can be volatile.

Comparison to Industry Standards

• Stock option repricing is a fairly common practice, especially in volatile sectors like biotechnology.
• Companies like Gilead Sciences and Amgen also use stock options as part of their compensation packages.
• The vesting schedules for RSUs (quarterly over four years) are fairly standard in the industry to promote long-term retention.

Stakeholder Impact

• The stock option repricing could potentially benefit shareholders if it motivates the executive to improve company performance.
• Employees holding similar options may also benefit from the repricing.

Key Dates

Keywords

stock options, RSUs, Eyal Attar, Vor Biopharma, repricing, insider trading, Form 4, executive compensation